It's time for bioethics and corporate interests to merge.
7/22/2002
The author, a scientist at Interleukin Genetics, argues that attempts to develop ethical solutions surrounding emerging biotech hotbeds must involve the full participation of the companies themselves: "Ethics cannot be forced into corporate practice," says Dhanda. More to the point, Dhanda lays out a blueprint for executives to become involved in this debate, focusing on four subjects: genetically modified crops, DNA data banking, personalized medicine, and stem cell research. Readers who might find this book useful include technologists, executives, and regulatory affairs officers inside of biotech companies, as well as bioethicists in the academic community.